---
title: "The biopharmaceutical sector saw a short-term surge, with CCHT hitting the daily limit up"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276843462.md"
description: "The biotechnology sector saw a short-term surge, with CCHT hitting the daily limit, Sunshine Guojian Pharmaceutical rising over 7%, and Olymvax Biopharmaceuticals, AMOYTOP, and RemeGen following suit"
datetime: "2026-02-25T06:40:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276843462.md)
  - [en](https://longbridge.com/en/news/276843462.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276843462.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/276843462.md) | [繁體中文](https://longbridge.com/zh-HK/news/276843462.md)


# The biopharmaceutical sector saw a short-term surge, with CCHT hitting the daily limit up

The biotechnology sector saw a short-term surge, with CCHT hitting the daily limit, Sunshine Guojian Pharmaceutical rising over 7%, and Olymvax Biopharmaceuticals, AMOYTOP, and RemeGen following suit

### 相关股票

- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-CN/quote/159102.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-CN/quote/560600.CN.md)
- [Sunshine Guojian Pharmaceutical (688336.CN)](https://longbridge.com/zh-CN/quote/688336.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md)
- [AMOYTOP (688278.CN)](https://longbridge.com/zh-CN/quote/688278.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [RemeGen (688331.CN)](https://longbridge.com/zh-CN/quote/688331.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md)
- [3SBIO (01530.HK)](https://longbridge.com/zh-CN/quote/01530.HK.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [REMEGEN (09995.HK)](https://longbridge.com/zh-CN/quote/09995.HK.md)
- [CCHT (000661.CN)](https://longbridge.com/zh-CN/quote/000661.CN.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-CN/quote/159615.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [Olymvax Biopharmaceuticals (688319.CN)](https://longbridge.com/zh-CN/quote/688319.CN.md)

## 相关资讯与研究

- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-CN/news/281458440.md)
- [Changchun High-Tech Industry's Unit Gets Nod for GenSci141 Ointment Clinical Trial](https://longbridge.com/zh-CN/news/276832823.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-CN/news/281662341.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-CN/news/280923090.md)